JP2018527323A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527323A5
JP2018527323A5 JP2018503151A JP2018503151A JP2018527323A5 JP 2018527323 A5 JP2018527323 A5 JP 2018527323A5 JP 2018503151 A JP2018503151 A JP 2018503151A JP 2018503151 A JP2018503151 A JP 2018503151A JP 2018527323 A5 JP2018527323 A5 JP 2018527323A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
polypeptide
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018503151A
Other languages
English (en)
Japanese (ja)
Other versions
JP6866345B2 (ja
JP2018527323A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/043267 external-priority patent/WO2017015433A2/en
Publication of JP2018527323A publication Critical patent/JP2018527323A/ja
Publication of JP2018527323A5 publication Critical patent/JP2018527323A5/ja
Application granted granted Critical
Publication of JP6866345B2 publication Critical patent/JP6866345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018503151A 2015-07-23 2016-07-21 Il−23a及びb細胞活性化因子(baff)を標的とする化合物及びその使用 Active JP6866345B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562196170P 2015-07-23 2015-07-23
US62/196,170 2015-07-23
US201562201067P 2015-08-04 2015-08-04
US62/201,067 2015-08-04
US201662355302P 2016-06-27 2016-06-27
US62/355,302 2016-06-27
PCT/US2016/043267 WO2017015433A2 (en) 2015-07-23 2016-07-21 Compound targeting il-23a and b-cell activating factor (baff) and uses thereof

Publications (3)

Publication Number Publication Date
JP2018527323A JP2018527323A (ja) 2018-09-20
JP2018527323A5 true JP2018527323A5 (cg-RX-API-DMAC7.html) 2019-08-08
JP6866345B2 JP6866345B2 (ja) 2021-04-28

Family

ID=57835236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018503151A Active JP6866345B2 (ja) 2015-07-23 2016-07-21 Il−23a及びb細胞活性化因子(baff)を標的とする化合物及びその使用

Country Status (21)

Country Link
US (3) US10280231B2 (cg-RX-API-DMAC7.html)
EP (1) EP3322436A4 (cg-RX-API-DMAC7.html)
JP (1) JP6866345B2 (cg-RX-API-DMAC7.html)
KR (1) KR102644875B1 (cg-RX-API-DMAC7.html)
CN (1) CN108135976B (cg-RX-API-DMAC7.html)
AU (1) AU2016297575B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018001255A2 (cg-RX-API-DMAC7.html)
CA (1) CA2993329A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018000182A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018001264A2 (cg-RX-API-DMAC7.html)
EA (1) EA201890360A1 (cg-RX-API-DMAC7.html)
IL (1) IL256665B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018000959A (cg-RX-API-DMAC7.html)
MY (1) MY191081A (cg-RX-API-DMAC7.html)
PE (1) PE20180774A1 (cg-RX-API-DMAC7.html)
PH (2) PH12021552628A1 (cg-RX-API-DMAC7.html)
SA (1) SA518390788B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201912593VA (cg-RX-API-DMAC7.html)
TW (2) TWI733685B (cg-RX-API-DMAC7.html)
UA (1) UA125433C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017015433A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
AP3953A (en) 2010-11-04 2016-12-22 Boehringer Ingelheim Int Anti-IL-23 antibodies
JP6293120B2 (ja) 2012-05-03 2018-03-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗IL−23p19抗体
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−23a関連疾患の処置に有用なバイオマーカー
EA201791734A1 (ru) 2015-02-04 2018-01-31 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения воспалительных заболеваний
CN108135976B (zh) * 2015-07-23 2022-10-18 博灵格英格尔海姆国际股份公司 靶向il-23a和b细胞激活因子(baff)的化合物和其用途
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3233261A1 (en) * 2021-09-30 2023-04-06 Langyong MAO Anti-il23 antibody fusion protein and uses thereof
AU2023416371A1 (en) * 2022-12-28 2025-07-17 Suzhou Transcenta Therapeutics Co., Ltd. Bispecific binding protein comprising anti-baff antibody and use thereof
CN121152636A (zh) * 2023-07-06 2025-12-16 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法
WO2025170982A2 (en) * 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US20100303777A1 (en) * 2006-12-14 2010-12-02 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
DK2245064T3 (da) 2007-12-21 2014-10-27 Medimmune Ltd BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
AR071698A1 (es) * 2008-05-09 2010-07-07 Abbott Gmbh & Co Kg Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
MX348166B (es) * 2008-12-19 2017-06-01 Macrogenics Inc Diacuerpos covalentes y sus usos.
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
RS61136B1 (sr) * 2010-02-19 2020-12-31 Xencor Inc Novi ctla4-ig imunoadhezini
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
SG187682A1 (en) * 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
AP3953A (en) * 2010-11-04 2016-12-22 Boehringer Ingelheim Int Anti-IL-23 antibodies
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
ES2720136T3 (es) 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
WO2012125850A1 (en) * 2011-03-16 2012-09-20 Amgen Inc. Fc variants
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CN104125852B9 (zh) 2012-02-15 2017-05-17 弗·哈夫曼-拉罗切有限公司 基于Fc‑受体的亲和色谱
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
EP3456741B1 (en) * 2012-05-22 2020-12-16 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
KR102181776B1 (ko) * 2012-06-05 2020-11-24 삼성전자주식회사 범용 디바이스에서의 파일 송/수신 장치 및 방법
WO2014100490A1 (en) * 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
JP2015088330A (ja) * 2013-10-30 2015-05-07 トヨタ自動車株式会社 硫黄含有全固体電池
WO2015100246A1 (en) * 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
WO2016039801A1 (en) * 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
CN108135976B (zh) * 2015-07-23 2022-10-18 博灵格英格尔海姆国际股份公司 靶向il-23a和b细胞激活因子(baff)的化合物和其用途

Similar Documents

Publication Publication Date Title
JP2018527323A5 (cg-RX-API-DMAC7.html)
RU2019120720A (ru) Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
HRP20191968T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
JP6157046B2 (ja) 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
CN108601830B (zh) 双特异性抗体平台
JP2020508655A5 (cg-RX-API-DMAC7.html)
JP2012514997A5 (cg-RX-API-DMAC7.html)
JP2015528003A5 (cg-RX-API-DMAC7.html)
HK1207575A1 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
JP2017509335A5 (cg-RX-API-DMAC7.html)
JP2019525738A5 (cg-RX-API-DMAC7.html)
RU2016139022A (ru) МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
JP2016507525A5 (cg-RX-API-DMAC7.html)
JP2020515518A5 (cg-RX-API-DMAC7.html)
JP2017504578A5 (cg-RX-API-DMAC7.html)
JP2017512063A5 (cg-RX-API-DMAC7.html)
RS65405B1 (sr) Multispecifična antitela koja olakšavaju selektivno uparivanje lakih lanaca
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
JP2021500348A (ja) 単一特異性抗体から多重特異性抗体を生成させるための方法
CA3064660A1 (en) Heterodimerizing ig domains
JP2022009816A5 (cg-RX-API-DMAC7.html)
BR112021000416A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a cd38
IL302575A (en) IL-2R BETA GAMMA c BINDING COMPOUNDS AND USES THEREOF
EP3641815A1 (en) A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY
KR20230118612A (ko) 헤테로다이머화를 위한 직교 돌연변이